Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma

Internal Medicine Journal

Volumn 35, Issue 12, 2005, Pages 726-728

  Henley, David ^a   Kaye, J ^b   Walsh, J ^b   Cull, G ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Bisphosphonate; Hypocalcaemia; Multiple myeloma; Pamidronate; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PAMIDRONIC ACID; PREDNISOLONE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPOCALCEMIA; KIDNEY DISEASE; LABORATORY TEST; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; PLASMACYTOSIS; PRIORITY JOURNAL;

EID: 29244451515     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2005.00949.x     Document Type: Article

References (15)

1. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20: 3719-36.
2. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-6.
3. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-72.
4. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-9.
5. Mishra A, Wong L, Jonklaas J. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001; 14: 159-64.
6. Champallou C, Basuyau JP, Veyret C, Chinet P, Debled M, Chevrier A et al. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. J Pain Symptom Manage 2003; 25: 185-90.
7. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Larson PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology.Philadelphia, PA: Saunders; 2003: 1303-71.
8. Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 2002; 119: 576-7.
9. Sims EC, Rogers PB, Besser GM, Plowman PN. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Clin Oncol 1998; 10: 407-9.
10. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004; 328: 335-6.
11. Chong G, Hoang T, Davis ID. Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients. Aust NZ J Med 1999; 29: 96-7.
12. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93.
13. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003; 98: 1735-44.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Zoledronic acid (Zometa) [computer program]. eMIMS 5.0. Sydney: MIMS Australia; August 2004.